New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 26, 2014
06:09 EDTLULU, VRTXStocks with implied volatility below IV index mean; LULU VRTX
Stocks with implied volatility below IV index mean; lululemon (LULU) 30, Vertex (VRTX) 43.
News For LULU;VRTX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 29, 2015
12:37 EDTVRTXStocks with call strike movement; VRTX GNW
Subscribe for More Information
06:11 EDTLULUStocks with implied volatility above IV index mean; LULU NAV
Stocks with implied volatility above IV index mean; lululemon (LULU) 45, Navistar (NAV) 45 according to iVolatility.
May 28, 2015
09:00 EDTVRTXPfizer has 'significant capacity' for additional deals, says JPMorgan
Subscribe for More Information
06:03 EDTLULUStocks with implied volatility above IV index mean; LULU NAV
Subscribe for More Information
May 26, 2015
07:41 EDTLULULululemon Athletica June weekly volatility elevated into Q1
Subscribe for More Information
06:03 EDTLULUStocks with implied volatility above IV index mean; ALTR LULU
Stocks with implied volatility above IV index mean; Altera (ALTR) 67, Marvell (LULU) 43 according to iVolatility.
May 21, 2015
11:04 EDTVRTXVertex has conference call hosted by JPMorgan
JPMorgan Analyst Kasimov hosts a conference call with CFO Ian Smith on May 26 at 1 pm.
10:43 EDTLULUOptions with increasing implied volatility
Options with increasing implied volatility: FTR LL XLNX LULU
10:30 EDTVRTXVertex management to meet with Maxim
Subscribe for More Information
May 19, 2015
07:56 EDTVRTXGilead for Achillion rumor not ridiculous, but highly unlikely, TheStreet says
Subscribe for More Information
May 17, 2015
13:46 EDTVRTXVertex reports Orkambi data, says 'significant improvements' in primary endpoint
Vertex Pharmaceuticals announced that the New England Journal of Medicine published data from the two phase 3 studies of Orkambi, or lumacaftor/ivacaftor, a medicine designed to treat the underlying cause of cystic fibrosis in people ages 12 and older with two copies of the F508del mutation. In November 2014, Vertex submitted an NDA to the FDA for the combination of lumacaftor and ivacaftor. On May 12th, the FDA’s Pulmonary Allergy Drugs Advisory Committee voted 12-1 to recommend approval of Orkambi for people ages 12 and older with two copies of the F508del mutation. The FDA is expected to make a decision by July 5. The New England Journal reports that the studies enrolled 1108 patients who underwent randomization and received Orkambi. In both studies, there were significant improvements in the primary end point in both lumacaftor–ivacaftor dose groups. The difference between active treatment and placebo with respect to the mean absolute improvement in the percentage of predicted FEV ranged 2.6%-4%, which corresponded to a mean relative treatment difference of 4.3 to 6.7%. Pooled analyses showed that the rate of pulmonary exacerbations was 30%-39% lower than in the placebo group. The rate of events leading to hospitalization or the use of intravenous antibiotics was also lower. The incidence of adverse events was generally similar to the placebo group.
May 15, 2015
12:47 EDTLULUAppeals court dismisses lululemon yoga pants lawsuit, Reuters reports
A lawsuit accusing lululemon of defrauding shareholders by failing to reveal the sheerness of its black Luon yoga pants has been properly dismissed by a U.S. appeals court, Reuters reports. The court ruled that "Insofar as the defendants are alleged to have omitted information from Lululemon's corporate website, filings with the SEC, press releases, or investor calls, the has failed adequately to plead with particularity that these omissions rendered the defendants' statements inaccurate, incomplete, or misleading or that the defendants were otherwise under a duty to disclose such information." Reference Link
09:31 EDTVRTXAmerican Thoracic Society to hold a conference
ATS 2015 Conference is being held in Denver on May 15-20.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use